In vivo anti-tumor activity of the organometallic ruthenium(ii)-arene complex [Ru(η⁶-p-cymene)Cl₂(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

Abstract

Based on the clinical success of platinum-based anti-cancer drugs, a variety of other metal-based anti-cancer compounds are being investigated.

Comparative solution equilibrium and structural studies of half-sandwich ruthenium(II)(η6-toluene) complexes of picolinate derivatives

“…Ru (III) complexes are considered as prodrugs that are activated by reduction and it provides the impetus for the development of various Ru(II) anticancer compounds [5]. It is noteworthy that a novel Ru(II) compound [Ru(4,4'-dimethyl-2,2'-bipyridine) 2 (RAPTA-C) possessing significant antimetastatic property and is ready for translation into clinical evaluation [10,11]; ii) the bidentate 1,2-ethylenediamine (en) containing Ru(II)-arene (RAED) complexes such as [Ru( 6 -biphenyl)(en)Cl]PF 6 (RM175) that possesses a similar cytotoxic activity to cisplatin [12,13]. In most of the half-sandwich organoruthenium(II)…”

Evaluation of Perylene Bisimide‐Based RuII and IrIII Complexes as Photosensitizers for Photodynamic Therapy

“…[8] Most prominent examples are NAMI-A, KP1339, and RAPTA-C, which are successfully proceeding in different stages of clinical trials. [9][10][11][12] Even more importantly for the metal-based PDT community, the Ru II polypyridyl complex TLD-1433 of the McFarland group (Figure 1) will soon start clinical trials phase Ib in Canada as a PDT agent against non-muscle invasive bladder cancer. [13][14][15] In the last years, our groups focused attention in the development of new Ru II -based PSs for PDT, antibacterial PDT (aPDT) and photoactivated chemotherapy (PACT).…”

The versatile ruthenium(II/III) tetraazamacrocycle complexes and their nitrosyl derivatives

“…However, cisplatin has undesirable side effects and its administration may also result in development of drug resistance, which led to investigation of second and third generation platinum compounds and platinum based treatments [225][226][227][228][229]. The toxicity of ruthenium(II) and (III) complexes is lower than that of cisplatin, and their kinetic behavior is similar to platinum with respect to cellular division processes [40,195,230,231]. This may be due to their ability to mimic iron and bind to diverse biomolecules, such as human serum albumin and the iron transport protein transferrin [219,232,233].…”